Novel Targets in Advanced Colorectal Cancer

Purpose of ReviewAlthough current guidelines suggest only testing for RAS and BRAF mutations as well as MMR deficiency in metastatic colon cancer, there are many other promising therapeutic targets that are being studied. We aim to review the recent literature and evidence behind some of these novel targets.Recent FindingsMany of these targets such as NTRK, ROS, ALK, and HER2 are being studied in current clinical trials and hold great potential in changing the treatment landscape for metastatic colorectal cancer.SummaryCurrent molecular testing algorithms may need to be expanded to allow better target discovery and for patients to benefit from more therapeutic options.